Study Phase 2

A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Topiramate on Electrophysiological Parameters in Subjects With Diabetic Peripheral Polyneuropathy

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous SystemProduct ClassAntiepilepticsPharmacological SubgroupAntiepilepticsChemical SubgroupOther AntiepilepticsCondition StudiedDiabetes Mellitus, Type 2
Sponsor Protocol NumberTOPMAT-NP-005Enrollment72Data PartnerJohnson & Johnson% FemaleN/AMean/Median Age (Years)N/A% WhiteN/A

Supporting Documentation

  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the clinical study report is available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.